| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2006-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4fa82d0efe600dcc7824479cdd16fdd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b218ab121a1e3c728720491e9b091944
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11695af1b9fb9402a11db69e1ae2a695 |
| publicationDate |
2007-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2620338-A1 |
| titleOfInvention |
Methods of using il-21 |
| abstract |
An allelic variation in the IL-21 receptor can result in reduced IFN-.gamma. production in individuals and can require administration of different doses of IL-21 to achieve therapeutic effects seen individuals that do not have the allelic variant. Based on the genotype of a patient's IL-21 receptor allele, methods of predicting therapeutic response to treatment with IL-21 are disclosed. Also disclosed are methods of selecting a therapeutic regimen for use of IL-21 in patients with variant IL-21 receptor alleles. |
| priorityDate |
2005-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |